“Why Wunderink Matters”


Sandra Steingard writes in Community Psychiatrist about Lex Wunderink’s study, published in the August JAMA Psychiatry, which found that people who discontinued medication have much higher rates of functional remission and full recovery. She also notes the work of Martin Harrow, Timothy Crow (who found in the ’80s “the disquieting conclusion that the benefits of active neuroleptics in reducing relapse may exact a price in occupational (employment) terms” in the long run), and Gleeson & colleagues, who found that intensive intervention to improve adherence produced no improvement in relapse and worse vocational outcomes.

Article →

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time


  1. Lex Wunderink’s findings refer to Halperidol, any similar work to Olanzapine? How safe to extrapolate to ‘atypicals’?
    Awareness of eg Tantam D/Prestwood ‘A mind of One’s Own’ A.S.simili, but when mistaken for Schizophrenia, iatrogenic results of medicalisation